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ABSTRACT 
 
In prokaryotes, transcription and translation are coupled and as a result, the beginning of the 
messenger RNA is translated by the ribosome while the 3' end is still synthesized. How 
exactly this occurs is still not clear. One possibility is that RNA polymerase and the 
ribosomes may be in physical contact with each other at some stage during gene expression 
or RNA polymerase has a binding site in the ribosomes. Mutational analysis is one method to 
explore how coordination between these two moieties occurs in bacteria. 
 
An Escherichia coli strain with all seven chromosomal ribosomal RNA operons deleted, 
replaced by a single rrnB plasmid-borne operon, was used to isolate ribosomal RNA mutants 
with increased rifampicin resistance, two of which were studied further. The altered rrnB 
operon in pGM1 was obtained by spontaneous whilst in pGM2 by EMS mutagenesis.  The 
mutated rrnB operon in pGM1 conferred resistance to 25µg/ml of rifampicin while in pGM2 
resistance of 30µg/ml was observed.  A base substitution of T to A at position 355 of the 23S 
rRNA was detected in pGM1and no nucleotide change was detected in pGM2. The successful 
isolation of ribosomal RNA mutants with rifampicin resistance is consistent with the 
hypothesis of interaction between the RNA polymerase and the ribosomes and suggests the 
part of this interaction is with the large ribosomal subunit. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1. Central dogma 
 
In all living organisms, gene expression is the process by which information stored in nucleic 
acid is used in the synthesis of a functional gene product. These products are often proteins, 
but in non-coding genes such as ribosomal RNA genes or transfer RNA genes, the product is 
a functional RNA. The process of gene expression is used by eukaryotes, prokaryotes and 
viruses to generate macromolecular components, usually proteins, used to sustain life. The 
central dogma of molecular biology governs the storage and transfer of information in DNA, 
RNA, and proteins. It is the frame of understanding the flow of information between genetic 
elements in living organisms. Since its formulation by Francis Crick in 1958, (Burian et al., 
1998) it has been used as a keystone in molecular biology.  
 
 
The transfer of information described by the central dogma is sequential, wherein one 
sequence of one biopolymer is used as a template for the construction of another biopolymer. 
Firstly, DNA is replicated by a complex group of proteins that unwinds the double-stranded 
helix and DNA polymerase to make more copies of the DNA. The replicated DNA is then 
used as a template to synthesize messenger RNA (mRNA) by RNA polymerase during a 
process called transcription. Transcription is followed by translation of the mRNA transcript 
into proteins by the ribosomes (Figure 1.1). 
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Figure 1.1: Central dogma of molecular biology and the flow of information indicating that 
genes are expressed by being transcribed from DNA to RNA with subsequent translation of 
the RNA transcript into a functional protein (Adapted from Crick, 1958). 
 
 
1.2. Coupled transcription-translation  
 
Transcription is the first major step of the expression of genes. In transcription, RNA 
polymerase synthesise an mRNA transcript from the coding strand of DNA. The second 
major step is translation, the process of making a polypeptide chain from an mRNA 
transcript. In eukaryotic cells, the nucleus and cytoplasm are separated by a nuclear 
membrane which means that after the mRNA is transcribed it has to be transported from the 
nucleus to the cytoplasm where it can be bound by ribosomes for translation.  
 
 
In contrast to eukaryotic cells, prokaryotic cells do not have a nuclear membrane separating 
the two cellular compartments. As a result, gene expression is the result of a coupled process 
between transcription by RNA polymerase and translation by the ribosome and its cofactors. 
RNA polymerase reads the three nucleotides for a codon in the DNA to produce mRNA at a 
similar speed as the translating ribosome decodes these three bases for extension of the 
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growing polypeptide by one amino acid. This means that the translation machinery that reads 
the mRNA follows the RNA polymerase as it extends the mRNA chain (Martin and Koonin, 
2006). Therefore prokaryotic transcription is coupled to translation (Figure 1.2). 
 
 
 
Figure 1.2: A prokaryotic cell showing an mRNA transcript being translated into protein by 
the ribosome (Adapted from French et al., 2007). 
 
 
How this occurs, if and how coordination happens, is not clear. In certain cases, depending on 
an efficient translation initiation frequency, the translation machinery can be close enough to 
the transcription machinery so one can anticipate transient physical interaction between the 
two machineries.  
 
 
1.3. RNA polymerase 
 
The RNA polymerase of Escherichia coli is a multisubunit enzyme that exists in two forms, 
namely the core and holoenzyme. The core enzyme has four polypeptide subunits: alpha (α), 
beta (β), beta′ (β′) in the stoichiometry α2ββ′ (Zhang et al., 1999). RNA polymerase 
holoenzyme has the same subunits as the core enzyme with an additional sigma (σ) subunit. 
The two α subunits assemble the enzyme and bind regulatory factors. Each subunit has two 
domains, namely α CTD (C-Terminal domain) which binds upstream of the extended 
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promoter and, α NTD (N-Terminal domain) which binds to the rest of the RNA polymerase. 
The β-subunit has the polymerase activity and is mainly involved in the synthesis of RNA. β′ 
binds non-specifically to DNA while ω restores disassociated RNA polymerase to its 
functional form and it has been reported to offer chaperone function in Mycobacterium 
smegmatis (Mukherjee and Chatterji, 2008). The σ-subunit helps to reduce the affinity of the 
core enzyme for non-specific DNA and greatly increases the affinity for the promoters during 
the initiation of transcription (Murakami et al., 2002). 
 
 
Table 1.1: Composition of bacterial RNA polymerase 
Subunit Molecular 
weight          
(kDa) 
Stoichiometry 
 
         Genes  
α    40         2            rpoA 
β   145         1            rpoB 
β'   160         1            rpoC 
σ   85         1           rpoD 
ω   10         1            rpoZ 
 
 
1.3.1. Action of RNA polymerase 
 
RNA polymerase catalyzes the synthesis of mRNA during transcription. Prokaryotic 
transcription is divided into three stages; initiation, elongation and termination. During 
initiation RNA polymerase core enzyme, associated with initiation factor (σ), forms an initial 
closed promoter complex by recognizing two hexamers of consensus DNA sequences: the 
Pribnow box (-10 element), centered at about -10 with respect to the transcription start site 
(+1), and the -35 element (Murakami, 2002). After binding to the DNA, transcription factors 
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unwind the DNA strand and allow RNA polymerase to transcribe only the antisense strand of 
DNA into mRNA. Transcription elongation involves the further addition of ribonucleotides 
as RNA polymerase moves along the DNA until it reaches a terminator sequence. At that 
point, RNA polymerase releases the mRNA polymer and detaches from the DNA.  
 
 
Figure 1.3: Mechanism of transcription by RNA polymerase. The anti-sense strand to be 
transcribed is depicted in blue. The incoming RNA polymerase holoenzyme (orange) binds to 
the promoter depicted in yellow.  The terminator sequence is depicted in green (Adapted 
from Orphanides and Reinberg, 2002).  
 
 
1.4. The ribosome 
 
The ribosome is a macromolecular complex of – in prokaryotes – three ribonucleic acid 
molecules (RNAs) and over fifty ribosomal proteins on which the second step of gene 
expression, translation, takes place (Elliott and Elliott, 2002). Ribosomes have been described 
as ribozymes since the rRNA seems to play an important role in the peptidyltransferase 
activity that links together amino acids during translation. In particular, the coupling of amino 
acids to form peptides (peptidyl-transferase reaction) is catalyzed by domain V of the 23S 
rRNA, known as the peptidyltransferase centre (Douthwaite, 1992). This structure has been 
highly conserved through evolution due to its role in translation. 
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The prokaryotic ribosome (70S) is made of two subunits referred to as the large (50S) and 
small (30S) subunits. In Escherichia coli the large subunit is composed of about 34 proteins 
and two rRNA components – the 5S and 23S of 120 and 2900 nucleotides in length 
respectively. The small subunit is composed of 21 proteins and 16S rRNA of 1540 
nucleotides in length (Yusupov et al., 2001). The rRNA component of the prokaryotic 
ribosome will be the main focus of this study. Hence, a more detailed discussion follows on 
the specifics of the rRNA components and their roles in translation. 
 
 
1.5. Antibiotics 
 
Antibiotics are chemical substances that kill, or inhibit the growth of other microorganisms. 
They are derived from Streptomycetes, which are predominantly found in soli and on 
decaying vegetation.These substances are secondary metabolites since their production is not 
required for the growth of the microorganism producing them. Large scale production is 
carried out using fermentation in an aerobic environment. Antibiotics are mainly classified as 
bactericidal; those that kills bacteria or bacteriostatic; those that inhibits the growth of 
bacteria (Blacheford and Cegange, 2006).  
 
 
The first antibiotic to be isolated was penicillin from Penicillium notatum by Alexander 
Fleming in 1929 (Diggins, 2003; Fleming, 1980). Penicillin was produced on a large scale 
using a culture of Penicillium notatum during the 1940s. The high demand for 
chemotherapeutic agents to treat wound infections during World War II led to the 
development of a production process for penicillin and this marked the beginning of an era of 
antibiotic research and continues to be a most fascinating area of microbial biotechnology 
even today. 
 
 
Antibiotics differ chemically and in the way they inhibit microorganisms. Certain antibiotics 
destroy bacteria by affecting the structure of their cell walls and cell membranes. Another 
way is by interfering with the organism′s metabolism. A large number of antibiotics (Table 
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1.1); such as macrolides, tetracyclines, and aminoglycosides are known to target the 
ribosome. This may be useful in the study of interaction between RNA polymerase and the 
ribosome.  
 
 
Table 1.2: Selected antibiotics and their targets 
Antimicrobial agent         Target 
 
Rifampicin 
 
β subunit of RNA polymerase 
Chloramphenicol 
 
Peptidyltransferase activity, 23S rRNA 
Erythromycin 
 
Exit tunnel, 50S subunit 
Kasugamycin 
 
P-site bound fMet from 30S subunit 
Streptomycin 
 
Formyl-tRNA of the 30S rRNA 
Tetracycline 
 
Docking of the amino-acylated tRNA in the 
16S rRNA 
(Vannuffel, and Cocito, 1996; Recht et al., 1999; Lambert, 2005). 
 
 
rRNA is the target of several antibiotics such as chloramphenicol (Mankin and Garrett, 
1991), erythromycin (Lucier et al., 1995; Gregory et al., 2001), kasugamycin (Vila-Sanjurjo, 
1999), spectinomycin (O′Connor and Dahlberg, 2002; Criswell et al., 2006), streptomycin 
(Honore et al., 1996), and thiostreptone (Thompson and  Cundliffe, 1996). In most cases, a 
single mutation in the rRNA may confer resistance to a particular antibiotic relating to the 
fact that they interact with the ribosome.   
 
 
In early functional studies of ribosomal mutations, much focus was on ribosomal proteins 
rather than the rRNA components. This was due to several reasons and amongst that was 
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because it was assumed that enzymatic activities had to be a function of proteins and mutants 
resistant to ribosomally-targeted antibiotics had alterations in the ribosomal proteins. 
Secondly, ribosomal proteins are relatively stable, and amenable to purification as compared 
to their rRNA counterparts. Lastly, isolation of rRNA mutants has been difficult due to the 
presence of multiple rrn operons in most experimental organisms. This probably reflects the 
need for high levels of protein synthesis in rapidly growing bacteria. For example, the E. coli 
(Asai et al., 1999) and Bacillus subtilis (Javis et al., 2000) genomes contain seven and ten rrn 
operons respectively. 
 
 
Resistance of many antibiotics, including streptomycin, spectinomycin and erythromycin, is 
“recessive” or weakly co-dominant to sensitivity when the mutation conferring resistance 
alters ribosomal proteins (Gregory and Dahlberg, 2009). Dominance of sensitivity is best 
documented for streptomycin-resistant mutations, in which streptomycin-resistant/sensitive 
merodiploids contain ribosome of both normal and altered types and are still nearly as 
sensitive to the bactericidal and bacteristatic activities of streptomycin as are streptomycin-
sensitive cells (Springer et al., 2001). Therefore, a mutation in an rRNA gene also might go 
undetected due to dominance of sensitive ribosomes that contain rRNA synthesized from 
non-mutant rrn operons in the same cell. This was observed in streptomycin, spectinomycin 
and erythromycin in early ribosomal mutation studies.  
 
 
1.6. Rifampicin 
         
Rifampicin (C43H58N4O12) has a molecular weight of 823 g.mol-1 (Tupin et al., 2010). This 
compound is an odorless red-brown crystalline powder which readily dissolves in methanol. 
The lipophilic characteristics of rifampicin contribute considerably to its ability to cross the 
cell wall barrier by passive diffusion. It is a broad-spectrum bacteriostatic drug that is 
predominantly used as the first-line antibiotics in the treatment of tuberculosis (TB), leprosy 
and a growing number of Gram-positive bacteria such as multidrug-resistant Staphylococcus 
aureus. Much of the membrane of this acid-fast Gram positive bacteria is mycolic acid 
complexed with peptidoglycan, which allows easy movement of the drug into the cell. 
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Rifamycins were discovered in 1959 by Sensi et al., produced by a strain of Amycolaptosis 
mediterranei (previously known as Streptomyces mediterranei and Nocardia mediterranei) 
and were introduced in therapy in 1962.  Rifamycins are active against a large variety of 
bacteria and some eukaryotes (Gardner et al., 1991). They have a broad activity against 
Gram-positive bacteria and, to a lesser extent, against Gram-negative bacteria 
(Pukrittayakamee et al., 1994). Ansamycins are structurally characterised by their planar 
naphthoquinone ring in which positions 3 and 4 have been extensively modified by 
hemisynthesis to yield commercial antibiotics such as rifampicin (Figure 1.4). 
 
 
Figure 1.4: The chemical structure of rifampicin (www.bikudo.com/rifampicin).  
 
 
The most important functional groups of rifampicin are the two free hydroxyl (OH) groups at 
positions 21 and 23 of the ansa ring ,  the two oxygen atoms (O1 and O2) at positions C1 and 
C8 and the unsubstituted hydroxyl groups (O10 and O9) at positions C21 and C23 of the 
naphthoquinone ring (Figure 1.4). These groups are considered to be essential for 
antimicrobial activity as they are involved in the formation of a tight but reversible linkage 
between rifampicin and RNA polymerase.  Modification of the ansa bridge or any 
modification that alter the conformation of the ansa bridge reduces antimicrobial activity of 
 - 10 -
this compound.  Any modification involving a substitution, change in molecular size of 
which is not important or elimination of the hydroxyl groups results in an inactive compound 
(Wehri and Staehelin, 1991). 
 
1.6.1. Mode of action 
 
The antimicrobial activity of rifampicin is due to it inhibiting DNA-dependent RNA 
polymerase by binding its β-subunit. This drug blocks the pathway of the elongating RNA 
transcript when it is 2 or 3 nucleotides long. The initiating nucleotide binds the RNAP i-site (i 
= initiation site at -1 position), while the second nucleotide binds at the i+1 site. After a 
phosphodiester bond has been formed between the two nucleotides, RNAP is translocated. 
Consequently, the i+1 nucleotide occupy the i-site at the -1 position and the i-site nucleotide 
moves into the -2 position (Campbell et al., 2001). 
 
 
The physical association of rifampicin to the β subunit of RNAP results in a severe steric 
clash with the 5′ triphosphate of the initiating nucleotide at the -2 position. Owing to the 
conformational change in the enzyme, the synthesis of the second phosphodiester bond is 
inhibited (Wehrli and Staehelin, 1991). Consequently, RNAP remains at the same template 
position, the 2 nucleotide transcript is released and this futile cycle resumes. The mechanism 
of RNAP inhibition by rifampicin is shown in Figure 1.5. If the third phosphodiester bond of 
the RNA transcript has been formed the drug is no longer able to exert its effect (Campbell et 
al., 2001). A possible explanation may be that the complex comprising the DNA template, 
RNAP and the RNA transcript, has undergone a conformational change, eliminating binding 
sites for rifampicin. 
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Figure 1.5: Mechanism of RNA polymerase inhibition by rifampicin (Adapted from 
Campbell et al., 2001). Mg2+ is represented by the magenta sphere. The incoming 
nucleotide substrate at the -1 position is shown in green and the -1 and -2 positions that can 
be accommodated in the presence of rifampicin are coloured in yellow. The RNA further 
upstream (-3 to -8) is coloured pink. The DNA template strand is grey. Rifampicin is shown 
positioned in its binding site on the β subunit. The carbon atoms are coloured in orange while 
the oxygen in red and nitrogen in blue, (Nicholls et al., 1991). The rifampicin is partially 
transparent, illustrating the RNA nucleotides (at -3 to -5) that sterically clash. 
 
 
1.7. Resistance to rifampicin 
 
Despite the highly efficient mechanism of inhibiting bacteria, rifampicin is by no means the 
perfect antibiotic. The biggest challenge arises from the fact that bacteria can acquire high 
level resistance to this drug through a variety of mutations. This is surprising, since the 
reason rifampicin works so well is that it is a rigid molecule, and sits tightly in the pocket 
where it binds, allowing the bonds to be very strong. However, this also means that if an 
 - 12 -
amino acid on the edge of the channel with a small side chain is replaced with an amino acid 
with a large side chain, rifampicin may not be able to bind, simply because it cannot fit in the 
space. Resistance to rifampicin by mutation of the target is widespread but not unique. Other 
mechanisms of resistance have been reported, such as duplication of the target, action of 
RNA polymerase-binding proteins, modification of rifampicin and modification of cell 
permeability (Tupin et al., 2010). 
 
 
1.7.1. Resistance by mutation of target 
      
Rifampicin interacts with the β-subunit of RNA polymerase encoded by rpoB gene. Binding 
of the molecule to RNA polymerase involves 12 amino acids residues and mutagenesis of at 
least one of the residues results in a resistant phenotype (Campbell et al., 2001). In E. coli, 
rifampicin resistance mutations are usually located in the central region of the polypeptide, 
within cluster I (amino acids 507-533), cluster II (amino acids 563-572) and cluster III (Floss 
and Yu, 2005), and they can also occur near the N-terminus of the β-subunit (Severinov et 
al., 1994). 
 
 
1.8. The ∆7 system  
 
Isolation of rRNA mutants was difficult because the rRNA genes are present as multiple 
copies in nearly all bacteria. This has become an obstacle to many studies of rRNA because 
the mutation in one rRNA gene would be masked by the rRNA originating from the other 
unaltered genes. For example, the E. coli (Asai et al., 1999) and Bacillus subtilis (Javis et al., 
2000) genomes contain seven and ten rRNA operons respectively. This is contrast to different 
Mycobacterium strains; Mycobacterium smegmatis has two rRNA operons while 
Mycobacterium leprae and Mycobacterium tuberculosis both have a single rRNA operon 
(Kempsell et al., 1992; Gonzales-y-Merchand, 1996).  
 
Several hypotheses have been proposed to explain the wide variation observed in rRNA copy 
number. It is generally assumed that the multiple copies of rRNA operons in prokaryotic 
organisms are required to achieve high growth rates. However, the marginal impact of rRNA 
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operons inactivation on the maximal growth rate (Condon et al., 1997) suggests that the 
capacity for rapid growth is not the sole determination of rRNA operon copy number. The 
number of transcripts that can be initiated at an rRNA operon promoter and the 
transcriptional rate of RNA polymerase set a maximum rate on the number of ribosomes that 
can be produced from a single rRNA operon. Given the high demand for rRNA transcription 
and the central role of rRNAs in the regulation of ribosome synthesis, it is conceivable that 
the number of rRNA operons may dictate the rapidity with which microbes can synthesize 
ribosomes and respond to favourable changes in growth conditions (Stevenson and Schmidt, 
2001). 
  
 
Despite the obstacle to rRNA studies due to multiple rrn operons in experimental organism; 
this can be overcome by the construction of an E. coli strain in which all seven chromosomal 
rRNA operons are inactivated by deletions spanning the 16S and 23S coding regions. A 
single E. coli rRNA operon carried by a multicopy plasmid supplies 16S and 23S rRNA to 
the cell. The ∆7 system has been used to successfully isolate rRNA mutants conferring 
resistance to antibiotics such as streptomycin (Finken et al., 2005), chloramphenicol 
(Kehrenberg et al., 2005), and tetracycline (Trieber and Taylor, 2002; Connell et al., 2003).  
 
 
1.9. Aim of the study 
 
The aim of this study was to investigate one possible explanation for coupled transcription-
translation coordination that occurs in prokaryotes. Since rifampicin is known to target RNA 
polymerase and rRNA is a central component of the ribosomal translation process, the focus 
of my work was to attempt to isolate rRNA mutants conferring resistance to rifampicin. 
Ability to isolate rRNA mutants on the ribosome that conferred resistance to rifampicin 
would suggest that there is indeed an intimate transient contact between the two moieties. 
This hypothesis of a possible intimate transient interaction between these two moieties is 
supported by the sigma operon observed in E. coli K12. This operon encodes DNA primase, 
the σ-subunit of RNA polymerase and 30S r-protein S21, which are essential for replication, 
transcription and translation respectively. Another example is the interaction of 50S r-protein 
L2 with the α-subunit of RNA polymerase (Rippa et al., 2010). These studies support the 
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hypothesis that there is indeed interaction of individual ribosomal proteins with RNA 
polymerase. 
 
 
Isolation of rRNA mutants was done by using an E. coli strain in which all seven 
chromosomal rRNA are deleted, and only one rRNA operon borne on a plasmid is present. 
Mutants were generated and screened using spontaneous or chemical mutagenesis and marker 
rescue to identify rRNA mutants. 
 
Specific experimental objectives: 
 
            1. To obtain rRNA mutants with altered resistance to rifampicin 
 
               2. To optimise the phenotypic expression of the mutant(s) 
 
                   3. Study the effects of mutations on other selected antibiotics 
 
                      4. Determine the nature and position of mutations by DNA sequencing 
 
  5. Perform site-directed mutagenesis to confirm that the mutations detected           
were responsible for the change in phenotype 
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CHAPTER 2 
 
 MATERIALS AND METHODS 
 
 
 2.1: Bacterial strains and plasmids used in this study 
 
Table 2.1: Bacterial strains used in this study 
Strains Characteristics            Source 
 
Escherichia coli   
          MM294-4 endA1, hsdR17, gyrA            E. Dabbs 
 
          SQZ10 ∆ 7 rRNA, pHK-rrnC+ SacB-
KanR, ptRNA67-SpcR  
           S. Quan 
          SQ170 ∆7 rRNA, pKK3535, 
ptRNA67-SpcR 
           S. Quan 
 
 
 
 
Table 2.2: Plasmids used in this study 
Plasmids Characteristics 
 
   Source/reference 
 
 
pDA71* E. coli-Rhodococcus shuttle vector 
with the EcoRI suicide gene 
inactivated 
 
   E. Dabbs 
pKK3535  pBR322 derived vector carrying an 
rrnB operon and  Amp-R marker 
 
   Brosius et al., 1981 
pGM1 ∆7 rRNA, pKK3535, ptRNA67, rif-R 
  
   This work 
pGM2 ∆7 rRNA, pKK3535, ptRNA67, rif-R    This work 
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pGEM-T-Easy E. coli cloning vector with lacZ′ 
gene, Amp-R, single 3′ thymidine 
overhangs, SP6 and T7 promoters                  
   Promega 
pKGEM EcoRI 2051bp fragment from 
pKK3535 ligated into pGEM-T-
Easy 
       This work 
pGM1-pKK7 pGM1 4293bp BamHI fragment 
ligated to the 7503bp BamHI 
fragment of pKK3535 
       This work 
pGM2-pKK7 pGM2 4293bp BamHI fragment 
ligated to the 7503bp BamHI 
fragment of pKK3535 
       This work 
 
 
pGM1-pKK4 pGM17503bp BamHI fragment ligated to 
the 4293bp BamHI fragment of pKK3535  
  This work 
pGM2-pKK4 pGM2 7503bp BamHI fragment ligated 
to the 4293bp BamHI fragment of 
pKK3535 
  This work 
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2.2. Media and growth conditions 
 
Luria-Bertani (LB) (Appendix) media was used for growing E. coli strains. Liquid cultures 
were obtained by inoculating a single bacterial colony into 5ml LB medium and incubated at 
37°C overnight. For short-term storage, E. coli strains were kept on LB-agar plates 
(Appendix) at 4oC and for long-term storage the strains were grown in 33% glycerol and kept 
at -70oC. 
 
 
2.3. Determination of minimum inhibitory concentration (MIC) 
 
The minimum inhibitory concentration of antibiotics was determined on LB-agar plates for E. 
coli by agar dilution method. Freshly grown single colonies were inoculated into 200µl of 
sterile distilled water per well of the replicator plate. This was then transferred to the 
antibiotic plates with a multipoint inoculator. Antibiotic-free plates were used as positive 
controls. The spot test results were analyzed after incubation at 37°C for 48- 72 hr.  
 
 
2.4. Plate patching technique 
 
This technique was employed to detect particular phenotypes of E. coli under varying 
conditions of antibiotic concentration. Individual colonies of E. coli were picked up using 
sterile toothpicks and streaked on LA and LA plates supplemented with an antibiotic. The 
streaking was done in a manner such that each individual colony could be identified on 
different LA plates. To achieve this, a numbered pattern was placed under each LA plate, and 
a streak was made on a particular corresponding number. The LA plates were then incubated 
for various duration of time (1-2 days) at 37°C. The phenotype was assessed based on the 
ability of the streaked cells to form confluent growth. 
 
 
 
 
 - 18 -
2.5. Marker rescue 
 
The marker rescue technique was used to confirm the mutations observed are plasmid-borne. 
A pool of resistant clones was grown in LB at 37oC overnight. Plasmid DNA was extracted 
and transformed into E. coli SQZ10. Transformants were selected on LA plates supplemented 
with 200µg/ml ampicillin and transferred to LA plates supplemented with 200µg/ml 
ampicillin and 6% sucrose (Appendix) after 24 hr. The presence of sucrose in the selection 
media makes the growth condition to be more favourable to the incoming plasmid, and thus 
displaces the resident plasmid. 
 
 
2.6. DNA preparations 
 
 
2.6.1. E. coli bulk plasmid preparations 
 
A single colony was used to inoculate 100 ml of LB with appropriate selective antibiotic for 
the maintenance of the plasmid. The culture was grown overnight with gentle agitation at 
37°C. Cells were harvested by spinning in a JA-10 rotor (Beckman) at 10 000 revolutions per 
minutes (rpm) for 10 minutes (min) and then resuspended in 5 ml of solution I (Appendix). A 
10 ml of solution II (Appendix) was then added to the cell suspension and mixed gently by 
inversion. The mixture was left to stand at room temperature for 15 min. Then 7.5 ml of 
solution III (Appendix) was added and shaken vigorously and then left on ice for 15 min.  
The cell debris were removed by spinning in a pre-chilled (4°C) JA-20 rotor at 15 000 rpm 
for 10 min. The supernatant was transferred to a sterile JA-20 centrifuge tube and the DNA 
was precipitated with 12ml of isopropanol. The precipitation process was allowed to continue 
at room temperature for 15minutes. This was followed by centrifugation at 15 000 rpm for 15 
min at room temperature. The supernatant was decanted off and the DNA pellet washed with 
2ml of ethanol. The ethanol was gently poured off and the DNA pellet was vacuum-dried for 
20 min. The DNA was re-suspended in 4ml TE buffer (Appendix) for 2 hours with gentle 
agitation. Thereafter, 4.1 g of cesium chloride (CsCl) was added and dissolved by mixing 
gently, followed by adding 600µl of 1% ethidium bromide (EtBr) (Appendix). The refractive 
index was adjusted to be between 1.387 and 1.389 (0.001 units =100mg CsCl if the index was 
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below or 0.001 units= 100µl TE if the index was above). The mixture was loaded into a 
Beckman Quick-seal tube using a Pasteur pipette. The tube was sealed, balanced and ultra-
centrifuged overnight at 45 000 rpm in a Beckman vertical VTi 65.2 rotor. The plasmid DNA 
was extracted from the tube using a needle attached to a hypodermic syringe. DNA was 
purified as described in section 2.7.1.3. 
 
 
2.6.2. E. coli mini plasmid preparations 
 
Individual bacterial colony was inoculated into 1ml of LB containing the appropriate 
selective antibiotic. This was incubated at 37°C with agitation overnight. The culture was 
transferred into sterile Eppendorf tube and the cells harvested by microfuging for 1 min. The 
supernatant was decanted off and the pellet resuspended in 80µl of solution I by vortexing 
briefly. Then 160µl of solution II was added to the cell suspension and mixed by gently 
inversion of the tube. The tube was left to stand at room temperature for 15 min. Thereafter, 
120µl of solution III was added and the mixture shaken vigorously and kept on ice for 5 min. 
Cellular debris was removed by microfuging at 4°C for 10 min. The supernatant was 
collected into a new sterile Eppendorf tube and placed in a water bath (42°C) for 2 min to 
warm the supernatant. Isopropanol (220µl) was added and the precipitation process allowed 
continuing at room temperature for 5 min followed by centrifuging at room temperature for 5 
min. The pellet was washed with 150µl ethanol and vacuum-dried for 20 min. The DNA was 
then resuspended in 100µl of sterile distilled water containing freshly boiled ribonuclease 
(RNaseA) (1µl of 10mg/ml). A small aliquot was analyzed for presence of plasmid DNA on 
0.8% agarose gel.  
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2.7. DNA manipulations and cloning techniques 
 
 
2.7.1. DNA precipitation 
 
 
2.7.1.1. Salt and ethanol precipitation 
 
DNA was precipitated from aqueous solution with 1/3 volume of 1M NaCl and 2 volumes of 
ethanol. The mixture was microfuged at 4°C for 20 min. The supernatant was decanted and 
the remaining liquid removed by blotting on a paper towel. The DNA pellet was vacuum-
dried for 10-20 min and resuspended in the appropriate volume of sterile distilled water. 
RNaseA (10mg/ml) was used to remove contaminating RNA. 
 
 
2.7.1.2. Isopropanol-mediated DNA precipitation 
 
 
After the addition of isopropanol (220µl), the solution was mixed by inversion and left to 
stand at room temperature for 5 min. The solution was then centrifuged at room temperature 
for further 5 min. The pellet was washed with 150µl of 96% ethanol and vacuum-dried for 20 
min. The plasmid was resuspended in an appropriate volume of sterile distilled water 
containing RNaseA.  
 
 
2.7.1.3. DNA precipitation from CsCl gradient 
 
 
Ethidium bromide was removed from the DNA by thorough mixing with 0.1 volume of 
butanol. EtBr suspended in butanol forms a top layer in the tube, which is removed. This 
procedure was repeated at least 3 times until there were no traces of EtBr. This left the DNA 
in CsCl solution. The DNA was stored at -20°C until required. The salt was removed by 
adding 2 volumes of sterile distilled water and 2.5 volumes of 96% ethanol and precipitated 
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by centrifugation at 4°C for 20 min. The pellet was vacuum-dried and resuspended in 
appropriate volume of sterile distilled water. 
 
 
2.7.1.4. Phenol-chloroform extraction 
 
 
The DNA solution in water was extracted by addition of 1/3 volume TE-saturated phenol 
(Appendix), mixed by inversion and microfuged at room temperature for 5 min to separate 
the organic and aqueous phases. The upper aqueous layer was transferred into a new sterile 
Eppendorf tube and where necessary, as in the case of extracting DNA from agarose gels, a 
further phenol step was performed. Then 1/3 volumes of chloroform was then added to the 
aqueous layer and mixed gently by inversion. The organic and aqueous layers were separated 
by microfuging at room temperature for 2 min. The upper aqueous layer was transferred into 
a sterile Eppendorf tube and the DNA was precipitated by the addition of 1/3 volume of NaCl 
as described in 2.7.1.1. 
 
 
 
2.7.2. Restriction enzyme digestions     
 
 
Enzymes were obtained from Fermentas and used according to manufacturer′s instructions. 
The total volume of digestion was 15µl (13.5µl DNA and 1.5µl 10× buffer). The mixture was 
tapped briefly to ensure even buffer distribution and spun down for 5 sec. 0.5-1µl of 
restriction endonuclease was added and the contents mixed and re-spun briefly. Digestions 
were incubated at the appropriate temperature for maximal enzyme activity for at least 4 hr. 
For double digestions an appropriate buffer in which both enzymes showed suitable activity 
was selected, otherwise the digestions were performed sequentially starting with the enzyme 
that require a lower incubation temperature.  
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2.7.3. Ligation of DNA    
 
T4 DNA ligase (Fermentas) was used for all ligations procedures. The total volume for 
ligation was kept minimal at 20µl. Vector DNA and insert DNA were added at a ratio of 1:3 
respectively. Ligation buffer and the appropriate volume of sterile distilled water were added 
to the DNA sample, mixed by tapping and microfuged for 5 sec. Subsequently, 1µl of ligase 
was added, remixed and re-spun. Ligation was performed in a water bath set at 22°C for 16-
22 hr. 
 
 
2.7.4. DNA extraction kit 
 
Purification of DNA bands excised from digested plasmids loaded on low-gelling agarose 
was performed by using a NucleoSpin Extraction II kit (Macherey-Nagel) according to 
manufacturer′s instructions. 
 
 
2.7.5. The freeze-squeeze method 
 
DNA was digested with appropriate restriction endonuclease and fragments were separated 
on agarose gel. The fragment of interest was excised from the gel with a scalpel while 
viewing under long wavelength UV light (366nm).  The gel slice was transferred into a sterile 
Eppendorf tube where it was crushed with a sterile spatula. The crushed slice of gel was kept 
at -70ºC for 30 min and it was thawed at room temperature. Following thawing it was 
microfuged for 6 min and the supernatant collected into a sterile tube. A second round of 
crushing, freezing, thawing and centrifuging was done. The DNA which was suspended in 
the collected supernatant was purified by phenol-chloroform extraction in 2.7.1.4. The DNA 
was re-suspended in appropriate volume of sterile distilled water.    
 
 
2.7.6. Determination of DNA concentration 
 
In order to measure the concentration of DNA solution, an aliquot was first run on a gel, 
which was then quantified using UVP LabWorks Image Acquisition and Analysis Software 
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(Ver.4.5) by comparing band intensity between the DNA and the molecular weight marker, 
for which the concentration had been predetermined by the manufacturers. 
 
 
2.7.7. Alkaline phosphatase treatment 
 
Fast thermosensitive alkaline phosphatase (Fermentas) was used to prevent the vector from 
ligating to itself. The alkaline phosphatase removes the 5′- phosphates that are necessary for 
ligation by DNA ligase. Without these phosphates the vector cannot ligate on its own but can 
still ligate to the insert that retains its 5′-phosphates (Weaver, 1999). Following digestion of 
the vector, 1µl of alkaline phosphatase and 5µl 10x fast alkaline phosphatase buffer was 
added to the reaction mixture. The reaction mixture was incubated for 10 min at 37°C 
followed by heat-inactivation at 80°C for 20 min. 
 
 
2.8. Gel electrophoresis 
  
 
2.8.1. Agarose gel electrophoresis 
 
Agarose solutions stock solutions were prepared in 0.5× TBE buffer (Appendix) at 
concentrations of 0.4%, 0.6% or 0.8% (Appendix) depending on a fragment size to be 
separated. The solutions were sterilized by autoclaving (121°C, 20 minutes). Fragment sizes 
≥10kb were analyzed on 0.4% agarose gels and 2-10kb on 0.8% agarose gels. Gels were 
prepared by melting the agarose stock solution in a microwave oven. A volume of 25ml of 
the melted agarose was mixed with 2.5µl of a 1% EtBr solution. The mixture was poured in a 
gel tray with a 12-tooth well comb and allowed to polymerize at 4°C for 20 min. Combs were 
removed when the gel had completely set.   
 
0.5× TBE electrophoresis buffer mixed with 1% EtBr solution was poured into an 
electrophoresis tank. DNA samples were loaded with 3µl of bromophenol blue tracking dye. 
GeneRuler TM DNA 1KB ladder Plus mix (Fermentas) was used in all electrophoresis runs 
using a Hoefer PS 500xdc power supply. The process was carried out at room temperature, 
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80V and a current of 21-28mA, until the dye front reached the bottom of the gel. DNA sizes 
were quantified from standard curve generated from migrations distances of known 
molecular weight marker sizes run on the same gel. The concentrations were estimated by 
comparing the intensity of the bands to bands of similar intensity and known concentration. 
The DNA was visualized and captured using the UVP BioDoc-ItTM system.  
 
 
2.8.2. Low gelling agarose gel electrophoresis 
 
Prior to usage, 20 ml of 0.6% low gelling agarose in 0.5× TBE buffer was autoclaved. EtBr 
was added to a final concentration of 1 mg/ml, and the agarose was poured into a tray 
inserted with a comb and polymerized at 4°C for 30 min. The gel was placed in a pre-cooled 
electrophoresis unit containing 0.5× TBE. DNA samples were mixed with bromophenol blue 
tracking dye and loaded into the wells; electrophoresis was conducted at 75 V at 4°C. Using a 
scalpel under a UV light, a band of interest was excised from the gel, from which the DNA 
was extracted by either phenol-chloroform extraction or freeze-squeeze method. In case of 
the phenol-chloroform extraction, the piece of agarose carrying the DNA was melted at 60°C 
for 30 min, followed by three phenol extractions. Between each extraction, 1/15 volume of 1 
M Tris-HCl (Appendix) was added. One chloroform extraction was then conducted, followed 
by precipitation of the DNA. 
 
 
2.9. Transformations 
 
 
2.9.1. E. coli CaCl2 transformation 
 
A flask containing 20 ml of pre-warmed LB supplemented with 0.5% glucose (Appendix) 
was inoculated with 200µl of an overnight culture of E. coli SQZ10. The culture was 
incubated with vigorous shaking at 37ºC until the OD600 of 0.2-0.4 had been reached. That 
OD was generally obtained by incubating for a minimum of 1hour 45 min - 2 hours. The 
flask was chilled in an ice-water slurry for 5 min and the cells were harvested in a pre-chilled 
Beckman JA-20 rotor at 10 000 rpm for 5 min at 4ºC. The supernatant was discarded and the 
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cells re-suspended in 10 ml of ice cold CaCl2 transformation buffer (Appendix). The cell 
suspension was placed on ice for 15 min and re-centrifuged at 10 000 rpm for 5 min. The 
supernatant was decanted and the cells re-suspended in 1.3 ml of transformation buffer. The 
cells were left on ice for 2-24 hours in the cold room (4ºC). 
 
  
Aliquots 100µl of the cell suspension were placed into pre-chilled sterile Eppendorf tubes and 
about 5-10µl of plasmid DNA was added and mixed with the cells by bubbling air through. 
The DNA plus cell suspension was left on ice for 15 min to allow for diffusion. The cells 
were then heat-shocked at 42ºC for 90 seconds. A volume of 500µl of pre-warmed LB was 
added to the cells after heat shocking and incubated for 1hr  at 37ºC to allow phenotypic 
expression of the resistance genes. The cells were then spread onto LB-agar containing an 
appropriate selective agent and further incubated for overnight at 37ºC. Colonies were visible 
after the overnight incubation for E. coli strains. 
 
 
2.9.2. Electroporation  
 
E. coli SQZ10 cells were prepared for electroporation by inoculating a fresh colony into 5ml 
of LB broth and incubated overnight at 37ºC. The overnight culture was then diluted 100× on 
LB broth and grown at 37ºC until the OD600 was <0.5. The cells were washed twice in 
electroporation buffer (Appendix) at 4ºC. An aliquot of 100µl of the E. coli cells was 
transferred into an Eppendorf tube and 5-10µl of DNA was added. This was mixed by 
bubbling air through and left to stand on ice for 10 min to allow diffusion. The mixture was 
then transferred into a pre-chilled electroporation cuvette and electroporated (25µF, 2.0kV 
and 200Ω). LB broth was added immediately to the electroporated cells and incubated for 1 
hour at 37ºC for the expression of the antibiotic resistance markers. After incubation the cells 
were plated on LB agar plates supplemented with an appropriate selectable marker and 
incubated overnight at 37 ºC. 
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2.10. Mutagenesis 
 
 
2.10.1. Ethyl methyl sulfonate (EMS) mutagenesis 
 
A clone in E. coli SQ170 was grown overnight at 37ºC in 5 ml of LB to an optical density of 
between 0, 2 and 0, 4. A 100 fold dilution of the culture was then grown in 5 ml of LB in a 
100ml flask to increase aeration and incubated at 37ºC for 4 hr. 1 ml of this culture was spun 
at room temperature at 15 000 rpm for 30 seconds. The cell pellet was then washed once 
using A-N buffer (Appendix) and the cells resupended in 500µl of the same buffer, and 500µl 
of a 2 % solution of EMS was added to the mixture. The culture was incubated at 37ºC for an 
hour. The cells were pelleted by microfuging for 30 sec at 13 000rpm and then washed using 
A-N buffer to stop the reaction. The cells were added to 5 ml of LB and incubated overnight 
at 37ºC. 100µl of the cells was spread on the appropriate plates and incubated overnight at 
37ºC. The EMS was detoxified by adding to a strong solution of sodium hydroxide before 
discarding. 
 
 
2.10.2. Polymerase chain reaction (PCR)-mediated site-directed mutagenesis 
(Adapted from www.finnzymes.com) 
 
A PhusionTM Site-Directed Mutagenesis Kit was used in this study. This is a PCR-base site-
directed mutagenesis which uses a highly processive PhusionTM hot start high-fidelity DNA 
polymerase for exponential PCR amplication of dsDNA plasmid that is mutated. PCR was 
performed in an MJ MINITM thermal cycler (Bio-Rad). The wild-type pKK3535 plasmid was 
used as a template. A control reaction utilised phosphorylated 5′ 
GTCGACTCTAGATCCCCGGGT 3′ and 5′ CTGCAGGACTGTAAGCTTGGCGTA 3′ as 
the forward and reverse primers respectively. PCR reactions were carried out in a total 
volume of 50µl as follows: 
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Table 2.3: Components of mutagenesis PCR 
Component Volume (µl) Final concentration 
5x Phusion buffer      10 1× 
10mM dNTP mix      1.0 200µM each 
Forward primer      1.0 0.5µM 
Reverse primer      1.0 0.5µM 
DNA template      1.0 2ng 
Sterile water      35.5 - 
Phusion DNA polymerase      0.5 0.02U/µl 
 
 
Table 2.4: Components of control PCR 
Components Volume (µl) Final concentration 
5x Phusion buffer      10 1× 
10mM dNTP mix      1 200µM each 
Control primer mix      1 0.5µM each 
Control plasmid      1 10pg 
Sterile water      36.5 - 
Phusion  DNA polymerase      0.5 0.02U/µl 
 
 
Finnzyme site-directed mutagenic PCR was used to introduce point mutations at specific 
positions of the rrnB operon of pKK3535. It exploits the high fidelity of Phusion hot start 
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DNA polymerase and the use of two phosphorylated primers. The, primers, one with the 
desired mutation, are designed so that they anneal back to back to the plasmid. 
 
The PCR reaction was performed under the conditions listed in Table 2.5. Twenty 
amplication cycles were carried out. Following PCR, the product was subjected to agarose 
gel electrophoresis to verify the amplication of the fragment of interest. The PCR product 
was then circularized by ligation with Quick T4 DNA ligase at room temperature for 5 min 
and transformed into E. coli. PCR conditions for the control plasmid are the same as the 
experimental plasmid, with the annealing cycle omitted.   
 
 
Table 2.5: PCR conditions used to amplify the rrnB gene 
 
Cycle Temperature (oC) Time (sec) Number of cycles 
Initial denaturation  
Denaturation 
      98 
      98 
    30 
    10 
       1 
       
Annealing       67.32     30       25 
Extension       72     3min, 36sec        
Final extension       72 
      4 
    10 
    hold 
      1 
      ∞ 
 
 
2.11. Preparation of DNA for sequencing 
 
DNA was prepared using GeneJet Plasmid Extraction Kit (Fermentas) according to 
manufactures instructions. This plasmid purification protocol is base on a modified alkaline-
lysis procedure, followed by the binding of plasmid DNA to a glass fibre matrix under the 
appropriate pH conditions. Plasmid DNA was eluted in a low ionic strength buffer. After 
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DNA had been prepared the concentration and purity of the DNA was analyzed on 0.8% 
agarose gel. Sequencing was performed by Inqaba Biotechnology Industries (Pty) Ltd. 
 
 
Table 2.6: Internet addresses used for sequence analysis and database access 
Program World wide web site 
Sequence analysis  
         BLASTN http://www.ncbi.nlm.nih.gov/BLAST/ 
         FASTA http://www.ebi.ac.uk 
         EMBOSS http://www.ebi.ac.uk/Tools/emboss/align/ 
         NEBcutter http://tools.neb.com/NEBcutter2/ 
Databases  
        GENEBANK http://www.ncbi.nlm.nih.gov/Genbank/ 
        EMBOSS Explorer http://embossgui.sourceforge.net/ 
        Reverse complement http://www.bioinformatics.org/sms/rev_comp.html 
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CHAPTER 3 
 
RESULTS 
 
 
3.1. Generation of an E. coli strain with a single rrnB operon 
 
 
E. coli SQZ10 is deficient of all seven chromosomal rRNA operons and carries plasmid 
pHK-rrnC+, which contains both the sacB and kanamycin resistance genes. To generate 
rRNA mutants, an E. coli strain carrying a single copy of the rrnB operon is desirable. This 
strain was generated by replacing plasmid pHK-rrnC+ in SQZ10 with pKK3535 (with the 
rrnB operon). This was done by transformation of SQZ10 with pKK3535 using both the 
CaCl2-mediated and electroporation methods.  Selection of transformants was done overnight 
on LA plates supplemented with 200µg/ml ampicillin. The results are indicated in Table 3.1 
below. 
 
 
Table 3.1: Transformation of E. coli SQZ10 with pKK3535 using optimized CaCl2-mediated 
transformation and electroporation techniques. 
Sample         Number of transformants (106)/µg DNA 
 
          CaCl2                    Electroporation 
No DNA               0                                0 
pDA71(vector control)             1.02                          11.59 
pKK3535             0.89                          7.93 
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Two transformation techniques, CaCl2 transformation and electroporation, were compared to 
determine the technique with a high transformation efficiency. A few transformants, in the 
case of the pKK3535 were anticipated when using the both the transformation techniques, 
because pKK3535 is a low-copy number plasmid as compared to pDA71. It was evident from 
Table 3.1 that the transformation efficiency of CaCl2 treated cells was at least ten times lower 
when compared to electroporation. Electroporation was chosen as the technique to be used in 
subsequent transformation experiments.  
 
 
To ensure that replacement of pHK-rrnC+ with pKK3535 was successful, five SQZ10 
transformants were screened for kanamycin-sensitivity and ampicillin-resistance. This was 
done by streaking single colonies on LA-Kan (100µg/ml) and LA-Amp (100µg/ml). Growth 
was only observed on LA-Amp plates, and no growth was seen on LA-Kan plates (Data not 
shown). This observation indicated that pHK-rrnC+ (confers kanamycin resistance) was 
replaced with pKK3535 (confers ampicillin resistance).This strain was designated E. coli 
SQ170 and used for subsequent selection of rifampicin-resistant mutants. 
 
 
3.2. Determination of sucrose concentrations lethal to E. coli SQZ10 
 
The sacB gene in E. coli SQZ10 codes for levansucrase, an extracellular enzyme that is 
responsible for the hydrolysis of sucrose and synthesis of levans, which are high molecular 
weight fructose polymers. Expression of sacB in the presence of sucrose is lethal to E. coli 
cells. An accumulation of levans which hinder the periplasm because of their high molecular 
weight or the transfer of fructose residues to inappropriate acceptor molecules promotes the   
toxic effects on the bacterial cells (Pelicic et al., 1996). It became obvious that prior to any 
mutagenesis and selection of rifampicin-resistant mutants, the concentration of sucrose 
sufficient to counter-select pHK-rrnC+ had to be determined.  
 
 
Literature indicates that when transforming mutated plasmid into the original host, a selection 
condition has to be in favour of the incoming plasmid in order to displace the resident 
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plasmid. This was done by streaking SQZ10 on LA-plates supplemented with increasing 
concentrations of sucrose (0%, 3%, 6%, 9% and 12%) and incubated overnight at 37oC.  
 
 
Figure 3.1: Inhibition of E. coli SQZ10 growth by different concentations of sucrose. 
pKK3535 was used as a positive control. 
  
 
It was confirmed that the growth of E. coli SQZ10 was inhibited by the presence of sucrose in 
the growth media.  Significant amount of growth was inhibited at 6% sucrose, and this was 
indicated by fewer colonies when compared with growth in a plate that was not supplemented 
with sucrose. 6% sucrose was chosen as the cut-off concentration to counter-select for the 
plasmid conferring resistance to kanamycin.  
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3.3. Selection of rifampicin-resistant SQ170 mutants 
 
 
3.3.1. Selection by spontaneous mutagenesis 
 
The first approach used to select SQ170 mutants with an increased MIC towards rifampicin 
was by spontaneous selection. Aliquots (100µl) of a culture of SQ170 were spread on broth 
plates supplemented with 25µg/ml, 50µg/ml, 75µg/ml or 100µg/ml rifampicin. The plates 
were incubated at 37oC until growth of resistant colonies was observed. The results are 
indicated in Table 3.2 below. 
 
 
Table 3.2: Rifampicin resistant clones obtained from spontaneous selection at 48 hr. 
Strain Rifampicin (µg/ml) Number of rif-R clones 
     24hr            48hr 
          0     
      
        25 
      +++              +++ 
 
      275               279 
 
 
        50       246              248 
 
        75       185              185 
 
       100       115              115 
+++ indicates confluent growth. 
 
 
3.3.2. Selection by EMS mutagenesis 
 
SQ170 was subjected to EMS mutagenesis and after overnight growth plated on LA plates 
supplemented with 50, 100,150 and 200µg/ml of rifampicin.  The number of resistant clones 
SQ170 
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obtained was 10-fold more when compared to those obtained by spontaneous selection and 
this is shown in Table 3.3 below. 
 
 
Table 3.3: Rifampicin resistant clones obtained from EMS mutagenesis at 48hr. 
Strain Rifampicin (µg/ml) Number of rif-R clones 
      24hr            48hr 
         0 
       50 
      +++                +++  
      2200              2320 
 
       100       1500             1500  
 
       150       1100             1100     
 
       200       789               800 
+++ indicates confluent growth 
 
 
The number of rifampicin resistant clones obtained by EMS mutagenesis was 10-fold more 
when compared to those obtained by spontaneous selection. This was expected, since EMS is 
a highly potent mutagen and has a mutagenesis rate that is considered to be higher than that 
of spontaneous mutagenesis. 
 
 
3.4. Identification of plasmid-borne mutations by marker rescue 
 
Using both spontaneous and EMS mutagenesis, rifampicin resistant mutants of SQ170 were 
generated. The purpose of the work was to obtain SQ170 mutants that carried rifampicin 
resistant mutations in the ribosomal RNA (i.e. plasmid-borne). To test if any of the rifampicin 
mutants carried such mutations; the marker rescue technique was employed. This pool of Rif-
R clones was washed off plates and grown overnight at 37oC in LB supplemented with 
100µg/ml ampicillin. A mini plasmid preparation of this pool was made. The DNA obtained 
SQ170 
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was utilized to transform E. coli MM294-4 cells via the CaCl2 method. A negative control of 
un-mutated SQ170 was included. Selection of transformed cells was done LA supplemented 
with Amp+6% sucrose only, followed by selection on LA-Amp/Rif plates. 
  
Transformation of SQZ10 failed to produce significant number of colonies when using 
electroporation. Initially it was thought that poor yield of transformants in SQZ10 was due to 
low yield of plasmid DNA. This proved not to be the explanation since when the same batch 
of plasmid DNA was transformed in E. coli MM294-4, a sufficient amount of transformants 
(±400) were obtained. To investigate this problem, a number of variables were changed. 
These included: 
 
1. Isolation of plasmid DNA using a Fermentas GenJet plasmid extraction kit to 
increase purity and quality of plasmid DNA  
  
2. Comparison of transformation efficiency of E. coli MM294-4 and SQZ10. 
MM294-4 has 20-fold more transformation efficiency than SQZ10. 
 
In spite of changing the above-mentioned parameters, the problem of low transformation 
efficiency still occurred. To settle the question of what caused a reduction in transformation 
efficiency even after optimization of electroporation conditions, transformation of SQZ10 
with a pool of Rif-R clones was repeated and selection of transformants was done in a three-
step process. Firstly, selection was done on LA-Amp only, followed by LA-Amp+6% sucrose 
and finally LA-Amp+Rif. Selection on LA-Amp only produced more than 4-times 
transformants as compared to when selection was done on Amp+sucrose. Results are 
recorded in Tables 3.4 and 3.5 below. The 3-step selection method was employed for further 
experiments of marker rescue. 
 
 
 
 
 
 
 
 - 36 -
Table 3.4: Transformation of SQZ10 with plasmid DNA (derived from a pool of Rif-R 
clones generated by spontaneous selection) from a Fermentas GeneJet Miniprep Kit using 
optimized electroporation conditions. 
SQZ10 transformed with DNA: No. of transformants on LA-supplement (µg/ml) 
          Amp200                   Amp100+6%sucrose 
No DNA              0                                        0            
SQ170             440                                    88 
SQ170-25             550                                    73 
SQ170-50             400                                    36 
SQ170-75             160                                    42 
SQ170-100             275                                    53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 37 -
Table 3.5: Transformation of SQZ10 with plasmid DNA (derived from a pool of Rif-R 
clones generated by EMS mutagenesis) from a Fermentas GeneJet Miniprep Kit using 
optimized electroporation conditions. 
SQZ10 transformed with DNA: No. of transformants on LA-supplement (µg/ml) 
   Amp200                        Amp200+6%sucrose 
No DNA       0                                           0 
SQ170      423                                        76                                 
SQ170-50      580                                        83 
SQ170-100      501                                        67 
SQ170-150      300                                        46 
 SQ170-200      150                                        42 
 
 
Marker rescue results revealed that Rif-R E. coli SQZ10 colonies were recovered with 
plasmid DNA derived from a pool of Rif-R clones, suggesting that the Rif-R phenotype 
observed was due to mutations in the plasmid DNA. 
 
 
3.5. Phenotypic characteristics of rRNA mutants 
 
3.5.1. Rifampicin phenotype 
 
The MIC of each mutant was determined by spot tests with concentrations of rifampicin 
ranging from 0 to 200µg/ml. Plates were incubated at 37oC for 24hrs and the results are 
shown in Figure 3.2 below. Six out of the 8 mutants tested displayed very slight growth at 
25µg/ml rifampicin. These clones were not studied further as it was believed that the colonies 
observed were low level resistant rRNA mutants. Only the MIC of the selected clones (pGM1 
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and pGM2) was studied further because they showed confluent growth on antibiotic plates. In 
E. coli SQ170, pGM1 and pGM2 conferred resistance up to 25µg/ml and 30µg/ml rifampicin 
as opposed to 5µg/ml for the un-mutated SQ170 control. This indicated an approximately 5-
fold increase in rifampicin resistance.   
 
 
Figure 3.2: Rifampicin MIC of rRNA mutants obtained from spontaneous selection and 
EMS mutagenesis in E. coli SQ170. Each set of experiments was repeated three times. The 
columns represent the average of results from all three experiments. Standard deviations of 
the means are indicated by error bars. 
 
 
3.5.2. Effects of temperature on rifampicin resistance 
 
E. coli SQZ10 cells, transformed with the rRNA mutants, were spotted onto increasing 
concentrations of rifampicin ranging from 0 to 200µg/ml. The plates were incubated at 18oC, 
25oC, 37oC, and 42oC for 24hrs. The MIC of each mutant was determined at varying 
temperatures in the presence (Figure 3.3.) and absence of ampicillin. Rifampicin resistance 
was higher in the absence of ampicillin. The results indicated that at low temperature, the 
resistance was reduced. Thus, the rifampicin resistance phenotype in SQ170 was determined 
to be cold-sensitive. At 42oC, resistance in pGM2 increased from 25µg/ml to 30µg/ml 
rifampicin. From the results observed, it was clear that pGM1 and pGM2 have different 
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temperature conditions that allow the phenotype of each mutant to be clearly 
expressed.pGM1, is expressed better at 37oC, whereas pGM2 phenotype is expressed better at 
42oC.  
 
 
Figure 3.3: Rifampicin MIC of rRNA mutants at varying temperatures of 18oC, 25oC, 
37oC, and 42oC in E. coli SQ170. Each set of experiments was repeated three times. The 
columns represent the means of results from all three experiments. Standard deviations of the 
means are indicated by error bars. 
 
 
3.5.3. Effects of pH on rifampicin resistance 
 
The MIC of the two mutants (pGM1 and pGM2) was determined by spot tests with 
concentrations of rifampicin ranging from 0 to 200µg/ml. Plates used for these tests were 
made from LA whose pH had been adjusted to pH 5.5 using HCl, pH 7.0, and pH 8.5 
adjusted by using NaOH. The results indicated that resistance was the highest at neutral pH 
and alkaline pH. There was a decrease in resistance at acidic pH. Both pGM1 and pGM2 
displayed an increase in resistance from 20 to 30µg/ml. The resistance of the SQ170 control 
was not affected by change in pH conditions as it remained the same in all the tested pH 
conditions. Results are shown in Figure 3.4 below. 
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Figure 3.4: Rifampicin MIC of rRNA mutants at varying pH conditions ranging from 
pH 5.5, 7.0 and 8.5 in E. coli SQ170. Each set of experiments was repeated three times. The 
columns represent the means of results from all three experiments. Standard deviations of the 
means are indicated by error bars. 
 
 
3.5.4. Effects of phosphate buffered media on rifampicin resistance 
 
The MIC of pGM1 and pGM2 was determined by spot tests on buffered L (A-N) media with 
varying pH values. The buffered LA-N was prepared by dissolving the required amount of 
bacteriological agar in water followed by adjusting the pH to the required values. This was 
followed by preparation of LB with the required pH. Both the LB and the agar were 
autoclaved separately and LB was supplemented with glucose and 1x A-N buffer. The two 
components then used to make rifampicin plates with varying concentrations ranging from 0 
to 50µg/ml. 
 
 - 41 -
 
Figure 3.5: Rifampicin MIC of rRNA mutants at varying pH conditions ranging from 
pH 5.5, 7.0 and 8.5 in buffered L (A-N) media. Each set of experiments was repeated three 
times. The columns represent the means of results from all three experiments. Standard 
deviations of the means are indicated by error bars. 
 
 
The growth patterns observed in Figures 3.4 and 3.5 suggests that the presence of phosphate 
buffer in the growth media did not have a significant effect on the resistance phenotype. This 
was most apparent at neutral pH 7.0 and alkaline pH 8.5 which showed a 4-fold and 5-fold 
increase in resistance of pGM1 and pGM2 respectively.     
 
 
3.5.5. Effects of plasmid-borne mutations on other antibiotics MICs 
 
Mutant pGM1 and pGM2 were tested for any increase or decrease in resistance to other 
antibiotics. For this purpose, antibiotics that were known to inhibit the translation process in 
different ways were chosen. The spot tests of pGM1 and pGM2 were done on varying 
concentrations of streptomycin, chloramphenicol, tetracycline, kasugamycin and 
erythromycin. The results are shown in Figures 3.6 to 3.10. E. coli SQ170 was used as a 
control strain.  
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The results indicated that the resistance/susceptibility of the strains was changed because of 
the presence of the mutation. pGM2 displayed a 2-fold increase in resistance to streptomycin 
when compared with E. coli SQ170. The results for pGM1 and pGM2 were comparable at a 
1-fold and 2-fold increase in resistance to chloramphenicol.  Both pGM1 and pGM2 were 
susceptible to tetracycline whilst no change in MIC was recorded for erythromycin on both 
mutants. pGM1 displayed no change in MIC and an increased susceptibility on pGM2 was 
observed.  
 
 
 
Figure 3.6: Streptomycin MIC of rRNA mutants in E. coli SQ170. Each set of 
experiments was repeated three times. The columns represent the means of results from all 
three experiments. Standard deviations of the means are indicated by error bars. 
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Figure 3.7: Chloramphenicol MIC of rRNA mutants in E. coli SQ170. Each set of 
experiments was repeated three times. The columns represent the means of results from all 
three experiments. Standard deviations of the means are indicated by error bars. 
 
 
 
Figure 3.8: Tetracycline MIC of rRNA mutants in E. coli SQ170. Each set of experiments 
was repeated three times. The columns represent the means of results from all three 
experiments. Standard deviations of the means are indicated by error bars.   
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Figure 3.9: Kasugamycin MIC of rRNA mutants in E. coli SQ170. Each set of 
experiments was repeated three times. The columns represent the means of results from all 
three experiments. Standard deviations of the means are indicated by error bars. 
 
 
 
Figure 3.10: Erythromycin MIC of rRNA mutants in E. coli SQ170. Each set of 
experiments was repeated three times.  
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Table 3.6: Summary of the effects of mutations on tested antibiotics MICs. 
  MIC (µg/ml)  
Antibiotic    
 pKK3535 pGM1 pGM2 
Rifampicin      5     25     30 
Streptomycin      2     2     4 
Chloramphenicol      2     3     4 
Tetracycline      4     2     2 
Kasugamycin            400     400     200 
Erythromycin      200     200     200 
 
 
These MIC findings were surprising, in particular the MICs of erythromycin and 
chloramphenicol. The mutation was expected to be in the 16S rRNA as supported by the MIC 
changes observed above. 
 
3.6. Restriction fragment exchange 
 
The mutants obtained by spontaneous selection and EMS mutagenesis were further 
characterized to differentiate between two types of plasmid mutations.  Restriction fragment 
exchange was performed to determine the type of mutation that was responsible for the 
changed phenotypes observed. Of particular interest were mutations that occur in the rrn 
RNA along the plasmid. 
 
 
Large scale plasmid preparations of the pool of rifampicin resistant clones and that of 
pKK3535 were done as described in 2.6.1. Plasmid DNA of the wild-type and the mutants 
were digested overnight with BamHI at 37oC. Digestion by BamHI generated two fragments 
of 7503bp and 4293bp.The larger  fragments, containing the rrnB operon, were separated 
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from the smaller fragments by extracting the bands from a 1% low-gelling agarose gel. The 
purified DNA fragments are indicated in Figure 3.11 below. 
 
 
Figure 3.11: Purified BamHI DNA fragments on 0.8% agarose. Lanes 1, 3, and 5 represent 
the 4293bp fragments of pKK3535, pGM1 and pGM2 respectively. Lanes 2, 4, and 6 
represents the 7503bp fragments of pKK3535, pGM1 and pGM2 respectively. 
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Figure 3.12: Restriction fragment exchange between the wild-type and the mutant 
recombinant plasmids.  
 
Inserts released by 
cleaving with BamHI 
Any colonies observed are 
due to rRNA mutants 
pKK3535 pGM1/pGM2 
pKK3535 pGM1/pGM2 
  
 
 
=Mutated rrnB operon of pGM1 or pGM2 
=Wild-type rrnB operon of pKK3535 
=Insert containing the mutated plasmid 
=Insert containing the original plasmid 
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All the 7503bp fragments were regarded as vectors and the 4293bp fragments as inserts. The 
vectors were treated with alkaline phosphate to prevent re-circularization. Each 4293bp 
fragments of pGM1 and pGM2 was ligated to the 7503bp fragment of pKK3535. Each of the 
7503bp fragment of pGM1 and pGM2 was ligated to the 4293bp fragment of pKK3535 and 
thus the fragments were exchanged (Figure 3.12). The DNA obtained was used to transform 
E. coli SQZ10 using the calcium-chloride method and selection of transformants was done on 
LA plates supplemented with 100µg/ml. The transformants were analysed for the presence of 
inserts to ensure that a confident representation of results had been attained. Transformants 
containing the vector ligated to the insert were observed and these were studied further. 
 
 
To ensure that ligation was successful, the transformants were grown overnight and plasmid 
DNA extracted. This was followed by digestion of plasmid DNA with BamHI to separate 
inserts from vectors.   
 
 
Figure 3.13: Plasmid DNA of pKK3535 digested with BamHI to release cloned inserts. Lane 
1 represents the molecular weight marker and lanes 2-4 represents the plasmid DNA with 
inserts released. 
 
 
    M        1        2          3         4         
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The transformants that contained the inserts ligated to the vector were streaked on LA-Amp + 
6% sucrose plates and then transferred to LA-Rif plates of 0µg/ml to 50µg/ml. Colonies of 
pGM1 and pGM2 that contained the mutated rrnB operon showed resistance growth on LA-
Rif plates whilst those with no mutations on the rrnB operon showed sensitivity to rifampicin 
(Data not shown). From the findings of the restriction fragment exchange, it was concluded 
that the mutations observed on pGM1 and pGM2 were rRNA mutations. 
 
 
3.7. DNA sequence analysis of rRNA mutants 
 
3.7.1. Nucleotide sequence analysis 
 
The rrnB sequences of pGM1 (obtained from spontaneous mutagenesis) and pGM2 (obtained 
from EMS mutagenesis) were analysed by internet databases. All two sequences were 
compared to the wild-type rrnB sequence using the Basic Local Alignment Search Tools for 
nucleotide alignments (BLASTn). 
 
The BLASTn search results detected base substitution for mutant pGM1 (Figure 3.12). The 
rrnB operon in pGM1 had a single base change from thymine to adenine at position 3681 of 
the wild-type sequence. No mutation was detected in the rrn region of pGM2 when its 
sequence was analysed with BLASTn. The observed phenotype of rifampicin resistance 
might be due to mutation(s) on the plasmid and not on the rRNA. To ensure the accuracy of 
the BLASTn database, the mutations were analysed using EMBOSS pairwise alignment tool. 
Using this tool, the same results were recorded for both the mutants. This suggested that the 
mutations detection of presence or absence of mutations was not because there is no change 
in the rrn region of the plasmid.   
 
The pGM1 mutation was on position 3681 of pKK3535 which places it in the 23S rRNA. 
This finding is surprising since the observation of the MICs of erythromycin and 
chloramphenicol, which targets the 23S rRNA, does not show much change in MIC and it 
was expected that the mutation was likely to be in the 16S rRNA. 
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Wt         3551 GGCCCAGGACACCGCCCTTTCACGGCGGTAACAGGGGTTCGAATCCCCTA   3600 
                |||||||||||||||||||||||||||||||||||||||||||||||||| 
pGM1       154  GGCCCAGGACACCGCCCTTTCACGGCGGTAACAGGGGTTCGAATCCCCTA    203 
 
 
Wt         3601 GGGGACGCCACTTGCTGGTTTGTGAGTGAAAGTCGCCGACCTTAATATCT   3650 
                |||||||||||||||||||||||||||||||||||||||||||||||||| 
pGM1       204  GGGGACGCCACTTGCTGGTTTGTGAGTGAAAGTCGCCGACCTTAATATCT    253 
 
 
Wt         3651 CAAAACTCATCTTCGGGTGATGTTTGAGATTTTTGCTCTTTAAAAATCTG   3700 
                ||||||||||||||||||||||||||||||.||||||||||||||||||| 
pGM1       254  CAAAACTCATCTTCGGGTGATGTTTGAGATATTTGCTCTTTAAAAATCTG    303 
 
 
Wt         3701 GATCAAGCTGAAAATTGAAACACTGAACAACGAGAGTTGTTCGTGAGTCT   3750 
                |||||||||||||||||||||||||||||||||||||||||||||||||| 
pGM1       304  GATCAAGCTGAAAATTGAAACACTGAACAACGAGAGTTGTTCGTGAGTCT    353 
 
 
Wt         3751 CTCAAATTTTCGCAACACGATGATGAATCGAAAGAAACATCTTCGGGTTG   3800 
                |||||||||||||||||||||||||||||||||||||||||||||||||| 
pGM1       354  CTCAAATTTTCGCAACACGATGATGAATCGAAAGAAACATCTTCGGGTTG    403 
 
Wt         3801 TGAGGTTAAGCGACTAAGCGTACACGGTGGATGCCCTGGCAGTCAGAGGC   3850 
                |||||||||||||||||||||||||||||||||||||||||||||||||| 
pGM1       404  TGAGGTTAAGCGACTAAGCGTACACGGTGGATGCCCTGGCAGTCAGAGGC    453 
 
Figure 3.14: Nucleotide alignment of the known rrnB operon sequence (wt) compared to its 
mutated pGM1 counter-part using BLASTN search programme. 
 
 
3.8. Site-directed mutagenesis of pKK3535 
 
As an alternative strategy, site-directed mutagenesis was used to confirm that the observed 
phenotype of pGM1 was due to the mutations detected in the rrnB operon. To do this, three 
single base mutations (T to A), (T to C), and (T to G) were introduced into the wild-type 
pKK3535 with the aid of a Finnzyme Phusion Site-Directed Mutagenesis Kit. This 
mutagenesis uses a high fidelity Hot Start DNA polymerase which only allows mutations to 
be introduced at positions of interest. Mutagenic primers were designed according to 
Finnzyme recommendations, with modifications as desired. 
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Table 3.7: Mutagenic primers used to construct 23S rRNA mutants 
Primer (5’-3’)       Tm (oC)      %GC 
Forward:GTGATGTTTGAGATATTTGCTCTTTAAAA        64.32       37% 
Reverse:CCGAAGATGAGTTTTGAGATATTAAGGTC        66.56       27% 
Forward:GTGATGTTTGAGATCTTTGCTCTTTAAAA        65.53       39% 
Reverse:CCGAAGATGAGTTTTGAGATATTAAGGTC        66.56       27% 
Forward:GTGATGTTTGAGATGTTTGCTCTTTAAAA        67.24       39% 
Reverse:CCGAAGATGAGTTTTGAGATATTAAGGTC        66.56       27% 
 
The site of adenine, cytosine and guanine insertion(s) are highlited in red. 
Tm was calculated as per formular supplied by the Finnzyme mutagenesis kit 
(www.finnzymes.com). 
 
 
Amplification was carried out in a PC-960G Gradient Thermal Cycler. The reaction 
parameters were set according to the Finnzyme specifications with the extension time of 
5min, 51sec. The PCR product was a linear plasmid molecule therefore it was circularized 
with the Quick T4 DNA ligase. The circularized plasmid was then transformed into E. coli 
MM294-4. DNA minipreparations of 5 transformants were performed and digested with to 
release the inserts.  
 
 
The purified PCR products were sent to inqaba Biotec for sequencing . Sequencing the PCR 
products was unseccessful due to a number of reasons. The sequences were analysed by 
bioinformatics tools and unfortunately no desired mutations were observed. It was speculated 
that this was due to that the DNA template (pKK3535) was large and thus the site-directed 
mutagenesis did not work. This was supported by the fact that the PCR product was a faint 
band. To improve the results, the DNA fragment with the position where the mutation was to 
be introduced was cloned into pGEM and thus the mutagenesis carried out. It was believed 
 - 52 -
that this would highly increase the efficiency and accuracy of the DNA polymerase during 
mutagenesis PCR because the DNA fragment to be mutated is shorter in length. 
 
To reduce the size of the template for optimum amplification, pKK3535 was digested with 
EcoRI to release a DNA fragment of 2051bp. The DNA fragment was cloned into pGEM and 
transformed into E. coli MM294-4. Transformants were screened for the presence of inserts 
by linearizing the DNA obtained from mini preparations with PstI. Successful amplification 
was carried as described above (Figure 3.15) and the PCR products were sent to Inqaba 
Biotec for sequencing. 
 
 
Figure 3.15: Amplified rrnB with desired mutations.  
 
After three attempts of site-directed mutagenesis and again no desired mutations were 
detected after DNA sequencing .  
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CHAPTER 4 
 
 
DISCUSSION 
 
 
4.1. Isolation of rifampicin rRNA mutations 
 
 
The E. coli genome carries seven rRNA (rrn) operons each containing a 16S, 23S and 5S 
rRNA gene. The presence of multiple operons has been an obstacle to many studies of rRNA 
genes because the effect of mutation(s) in one operon is diluted by the remaining six wild-
type copies. In light of the above statement, genetic efforts to study the interaction of the 
ribosome and RNA polymerase have been difficult. The development of an E. coli system 
that carries a single rRNA operon located on a plasmid (Asai et al., 1999) has helped 
overcome a large gap in the understanding of the function of rRNA; of particular interest 
being is there a physical but perhaps transient interaction of ribosomes and RNA polymerase 
during coupled transcription-translation in bacteria. In this context the contribution of 
research into antibiotics that target transcription and translation machinery has been fruitful 
for furthering the understanding of functional interactions between these cellular structures. 
Thus, it became possible to isolate rRNA mutants that confer antibiotic resistance to E. coli 
and to locate the positions where the mutations occur on the rRNA.  
 
 
Rifampicin is a chemotherapeutic agent used to combat infections by pathogenic 
nocardioforms and Mycobacterium tuberculosis. Soon after its introduction to clinical 
practise in 1972, resistant mutants were identified (Gillespie, 2002). Resistance has been 
primarily through target site alteration but in addition four inactivation mechanisms has been 
identified, but only mutation  by alteration of target site will be discussed as it is the main  
focus in this study. 
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A strategy was developed for the generation of rifampicin resistance mutants in the rRNA of 
E. coli. This involved the use of a previously described SQ170 strain that is deficient of all 
seven chromosomal rrn operons. Mutants of this strain would be generated by spontaneous 
and chemical mutagenesis, and selected directly for the desired phenotype of rifampicin 
resistance. Furthermore, it should be possible to select into the host strain, since only one 
plasmid-borne rRNA operon was present in this background. 
 
 
4.2. Mutational analysis of rRNA    
 
Two rifampicin resistant rRNA mutants were characterised in this work. These were pGM1 
(obtained from spontaneous selection), and pGM2 (obtained from EMS mutagenesis). The 
nature of the mutations in each of these mutants was examined in terms of nucleotide 
substitutions. The implication of these changes on the functioning of the rRNA and how 
ribosomal proteins (r-proteins) will interact with the region of rRNA will then be considered. 
These are important as it is known that there is a high cooperative nature of the interaction 
between rRNA and r-proteins that is essential for functional translational activity. r-proteins 
do affect the function of ribosomes, as is mostly clearly evidenced by mutations in r-protein 
genes that change the rRNA structure (Gregory and Dahlberg, 1999), ribosome sensitivity to 
antibiotics and the accuracy at which the ribosome translates the genetic code (Gao et al., 
2003). 
 
 
The ability to successfully isolate rRNA mutants conferring resistance to rifampicin in this 
study suggests that there either is a hitherto unknown but weak rifampicin binding site on the 
ribosome or that there is an intimate transient contact between RNA polymerase and the 
ribosome during gene expression. The detailed molecular mechanism of this contact would 
be the subject of future work. 
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4.2.1. Mutational analysis of pGM1 
 
The rRNA gene in pGM1 had a single base substitution from thymine to adenine at position 
355 of domain I in the 23S rRNA.  Figure 4.1 shows a 3D-structure of the large ribosomal 
subunit, indicating different domains of the subunit, which gives insight on where the 
mutation is situated. This transversion might lead to structural changes in the large subunit 
either in terms of tertiary structure of the large subunit RNA or it may affect the way 
ribosomal proteins interact with this subunit.  
 
 
4.3.2. Mutational analysis of pGM2 
 
No base substitution mutation was detected in the nucleic sequence analysis of the rrn region 
of pGM2. Sequencing errors were ruled out as the cause after sequencing was repeated twice 
and the same results were observed. Since this was the case for this mutant, we reasoned that 
the observed phenotype of rifampicin resistance could have resulted from a mutation 
elsewhere on the plasmid rather than the 23S RNA gene.  
 
 
 
Figure 4.1: Tertiary structure of the large ribosomal subunit domain I in Haloarcula 
marismottui (Adapted from Ban et al., 2000). An arrow indicates the position of the mutation. 
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In terms of the MIC changes observed in chloramphenicol and erythromycin, the mutation is 
expected to be in the small rRNA but this was not the case when the DNA sequences were 
analysed. This finding is surprising since the observation of the increased MICs of 
streptomycin and kasugamycin while erythromycin and chloramphenicol, which target the 
23S rRNA, did not show much change in MIC and this strongly indicates that the mutation is 
likely to be in the 16S rRNA.  
 
 
4.3. Identification of r-proteins associated with RNA polymerase 
 
The assembly and mechanism of the ribosome involve the cooperative interaction of r-
proteins and RNA components. This is observed by the many r-proteins that permeate the 
large subunit extensively by making van der Waals forces with the nucleotides. Considerable 
evidence indicates the participation of r-proteins both in the stabilization of the proper rRNA 
tertiary structure and in facilitating dynamic conformational changes of rRNA during protein 
synthesis (Gregory and Dahlberg, 1999). Numerous proteins have been recorded to interact 
with Domain I of the large subunit, where the mutation of pGM1 is. These proteins include 
L4, L15, L22, L24, L29, L37e, L39e, and L44e (Figure 4.2).   
 
A       B 
        
Figure 4.2: Proteins that appear on the surface of the large ribosomal subunit. (A) The 
crown view of the subunit. (B) The back side of the subunit in the 180oC rotated crown view 
orientation (Adapted from Ban et al., 2000). 
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A study by Dabbs (Dabbs, 1979) reported that r-proteins L15, L24 or L29 are not essential 
for the translational function of the ribosome, since mutations lacking these proteins are 
viable although some of them show severe defects indicated by conditional lethality 
(temperature sensitivity). But recently, studies have contradicted this statement. Stelzl et al., 
2000 reported that L15 is essential for the late assembly step that is important for an active 
ribosomal conformation and binds erythromycin in solution whereas L24 plays an important 
role for assembly initiation by forming an assembly starting point at the 5’end of 23S rRNA. 
Mutations in L4 and L22 have been reported to confer resistance against erythromycin, by 
interfering with the binding site of the drug. Erythromycin blocks the insertion of the growing 
peptide chain into the tunnel of the large ribosomal subunit (Stelzl, et al., 2000). A recent 
study by Rippa et al., 2010; reported interaction of a 50S r-protein L2 with the α-subunit of 
RNA polymerase.  
 
 
4.5. Conclusions 
 
In summary, successful isolation of Rif-R rRNA mutants is consistent with the hypothesis 
that there is intimate transient contact between the ribosome and RNA polymerase in 
bacteria. Furthermore, based on the position of the mutation we determined that RNA 
polymerase might contact the ribosome in the region of proteins L4, L15, and L22. Screening 
of a large number of ribosomal protein mutants (Dabbs and Wittmann, 1976) revealed several 
with altered rifampicin MIC (Dabbs, personal communication). The applications of these 
findings in molecular biology will enhance our understanding of the nature how the 
interacting proteins in stable complexes are essential to understanding the mechanisms that 
regulate cellular processes at molecular level. 
 
 
4.6. Future work 
 
Additional experiments could in future distinguish between the alternatives. These include 
rRNA mutations suppressing a conditional lethal (Ts or cs) rpoB rifampicin resistance or by 
doing cross-linking experiments involving the ribosome and RNA polymerase.  Positive 
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results for either of these would support the contact model since if the 23SRNA mutation 
alters a hitherto unknown weak rifampicin binding site such outcomes would not be expected. 
 
Rifampicin mutations in the rpoB gene may be conditionally lethal. Conditions such as 
temperature can be used to suppress the Rif-R phenotype and intergenic suppressors can be 
determined by marker rescue. The presence of suppressor mutations that have Rif-R rRNA 
mutants at a different site than the original site would support that RNA polymerase or 
rifampicin has a binding site in the ribosome. 
 
 
The interaction of RNA polymerase and r-proteins in a cell can be investigated by 
crosslinking experiments. A chemical crosslinker, which is sensitive to the desired proteins, 
can be used to probe these proteins and link them together. Protein interactions are often too 
weak or transient to be easily detected, but by crosslinking, the interactions can be captured 
and analyzed. 
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CHAPTER 6 
 
APPENDICES 
 
APPENDIX A: MEDIA  
 
Luria Bertani (LB) broth 
Tryptone     3g 
Yeast extracts     1.5g 
NaCl      1.5g 
Distilled water    300ml 
 
LA (Luria Bertani agar) 
Tryptone     3g 
Yeast extracts     1.5g 
NaCl      1.5g 
Agar      4.5g 
Distilled water    300ml 
 
LAS (LA supplemented with 8% sucrose) 
Tryptone     3g 
Yeast extracts     1.5g 
NaCl      1.5g 
Agar      4.5g 
Sucrose     18g 
Distilled water    300ml 
 
L (A-N) 
Tryptone     3g 
Yeast extracts     1.5g  
NaCl      1.5g 
Agar      4.5g 
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10× A-N buffer    10ml 
Distilled water     300ml 
pH was adjusted to pH 5.5, pH 7.0, and pH 8.5 as required for experiments. 
 
 
APPENDIX B: SOLUTIONS 
 
A6.1: Solutions used for plasmid preparations from E. coli 
 
Solution I 
Glucose     0.9g 
1M Tris-HCl (pH 8.0)               2.5ml 
EDTA (pH 8.0)    2ml 
Distilled water    95.5ml 
 
Solution II 
NaOH      0.8g 
SDS      1g 
Distilled water    100ml 
 
Solution III 
5M CH3COOK solution   60ml  
CH3COOH     11.5ml 
Distilled water    28.5ml 
 
RibonucleaseA 
10mg/ml solution in sterile distilled water, heated to 96ºC immediately before use 
 
1M Tris-HCl pH 8.0 
Tris-HCl     15.8g 
Distilled water    100ml 
Autoclave 
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0.5M EDTA pH 8.0 
EDTA      18.6g 
Distilled water    100ml 
Adjust to pH 8.0 with NaOH 
 
5M CH3COOK (pH 6.0) 
CH3COOK     4.9g  
Distilled water    100ml 
Adjust to pH 6.0 with CH3COOH 
 
A6.2: Solutions used for transformations 
 
CaCl2 Transformation buffer 
Tris-HCl (pH 8-0)    20mM 
CaCl2                  100mM 
pH adjusted to pH 8.0 and the solution autoclaved. 
 
20% Glucose 
Glucose     4g 
Distilled water    20ml 
 
 
A6.3: Solution for DNA analysis 
 
Agarose gels 
Agarose     0.8g (0.4%), 1.2g (0.6%) or1.6g (0.8%) 
0.5× TBE     50ml 
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5 × TBE buffer 
Tris base     54.0g 
H3BO3      27.5g 
0.5M EDTA     20ml, pH 8.0 
Distilled water    1000ml 
Autoclave 
 
Bromophenol blue tracking dye 
30% glycerol (w/v) in TE and 0.0025% bromophenol blue  
 
Running buffer (0.5x TBE) 
5× TBE      50ml 
Distilled water    450ml 
 
Molecular weight markers 
6× loading dye    100µl 
Sterile distilled water    400µl 
Molecular weight marker   100µl 
 
TE buffer 
1M Tris-HCl (pH 7.5)    10ml  
500mM EDTA (pH 8.0)   2ml 
Distilled water     88ml 
 
TE-saturated phenol 
Phenol      14g 
TE buffer     10ml 
 
6.4: Solutions for mutagenesis 
 
10× A-N buffer 
K2HPO4     70.0g 
KH2PO4     26.8g 
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Na3C6H5O7     5.0g 
MgSO4       1.0g 
Distilled water        1000ml 
 
 
Table A6.1: Antimicrobial agents 
Agent   Stock (mg/ml)                 Solvent       Supplier 
   
Ampicillin  100  70% ethanol  Sigma-Aldrich 
Chloramphenicol 20  ethanol  Boehringer Mannheim  
Erythromycin  20  ethanol  Boehringer Mannheim 
Kanamycin  10  sdH2O   Melford  
Kasugamycin  100  sdH2O   Boehringer Mannheim 
Nalidixic Acid 10  sdH2O   Sigma-Aldrich 
Rifampicin  10  methanol  Sigma-Aldrich 
Streptomycin  20  ethanol  Boehringer Mannheim 
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Table A6.2: Chemical suppliers 
Name of the chemical     Supplier 
Agarose       Bio-Rad 
Acetic acid       Merck 
Bacteriological agar      Biolab 
Boric acid       Saarchem 
Bromophenol blue      Sigma-Aldrich 
Cesium chloride      Sigma-Aldrich 
Chloroform       Saarchem 
Dipotassium hydrogen Phosphate    Merck 
EDTA        Sigma-Aldrich 
EMS        Sigma-Aldrich 
Ethanol       Saarchem  
Ethidium bromide      Sigma-Aldrich 
Glucose       Fluka Biochemika 
Glycerol       Merck    
Hydrochloric acid      Merck 
Isopropanol       uniLAB 
Magnesium sulphate      Sigma-Aldrich 
Potassium acetate      Sigma-Aldrich 
Potassium dihydrogen phosphate    AnalaR-analytical reagents  
Phenol        Saarchem  
RNaseA       Sigma-Aldrich 
SDS        Boehringer Mannheim 
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Sodium chloride      Saarchem 
Sodium hydroxide      Saarchem 
Sucrose       Supermarket 
Tri-sodium citrate      Sigma-Aldrich 
Tris-HCl base       Saarchem 
Tryptone       Biolab 
Yeast extracts       Biolab 
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APPENDIX C: PLASMIDS AND MOLECULAR WEIGHT MARKERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A6.1: Restriction map of pDA71 (adapted from 
http://seq.yeastgenome.org/vectordb/vector.html) 
 
 
 
Figure A6.1: Restriction map of pDA71 
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Figure A6.2: Restriction map of pKK3535 (Brosius et al., 1981) 
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Figure A6.3: Restriction map of pGEM-T-Easy (Adapted from www.promega.com) 
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Figure A6.4: 1Kb DNA ladder plus, Fermentas 
(http://www.fermentas.com/catalog/electrophoresis/generulers.htm). 
 
 
 
